Infectious Disease Billing Companies in Virginia

CPT code 86480 is used to report an immunoassay for tuberculosis infection, including testing methods such as an interferon-gamma release assay. The code describes the laboratory testing service rather than a particular payer’s coverage decision. Coding and reimbursement can depend on documentation, medical necessity, payer policy, and whether the service is billed by the appropriate laboratory or healthcare provider.

A QuantiFERON-TB Gold test is a blood-based interferon-gamma release assay used to help detect immune reactivity associated with Mycobacterium tuberculosis. It is commonly considered when evaluating tuberculosis infection and does not require the patient to return for a skin-test reading. A clinician interprets the result alongside symptoms, history, exposure information, and other clinical findings.

QuantiFERON-TB Gold may be covered when the test meets a health plan’s medical-necessity and policy requirements, but coverage is not universal. Patient benefits, diagnosis documentation, ordering location, laboratory billing, and payer rules can affect payment. Practices should verify eligibility and benefits, review applicable authorization requirements, and explain potential patient responsibility before testing when feasible.

Infectious disease billing can include evaluation and management services, hospital consultations, infusion administration, drug claims, OPAT-related services, laboratory testing, authorizations, denials, and accounts receivable follow-up. A strong workflow connects clinical documentation, coding, charge capture, payer requirements, and payment reconciliation. The exact services and billing responsibilities vary by practice structure, contracts, and service lines.

Infusion and drug claims can involve separate charges for the medication, administration, units, coding details, authorization, and benefit classification. Errors or gaps in any part of that chain can create denials, delays, or underpayments. Reviewing documentation, authorization status, drug and administration charges, payer rules, and payment results together helps practices locate the source of a billing problem.

Denial reduction starts with categorizing denials by root cause rather than treating every rejection as an isolated event. Common review areas include missing authorization, medical-versus-pharmacy benefit confusion, drug and administration coding, and incomplete consult documentation. Practices can then update workflows, strengthen front-office and clinical handoffs, and use payer-specific appeal and correction processes where appropriate.

Revenue-cycle consulting can review the workflow from referral through final payment, including documentation, coding, eligibility, prior authorization, drug acquisition, infusion billing, denials, underpayments, A/R follow-up, and coverage agreements. The objective is to identify where revenue is delayed, lost, or left uncollected and connect each issue to a practical operational improvement.

Practices can examine performance by payer, service line, provider, claim status, denial reason, payment result, and accounts receivable balance. Reviewing trends can reveal under-leveled visits, uncaptured drug or administration charges, repeated authorization issues, contract payment discrepancies, and aging claims. Using the practice’s own data supports more meaningful decisions than relying on generalized rates or margins.